EUVIMEDEUVIMED entdecken
Crossref

Lipid-lowering agent use and changes to sleep

Mariam Belghiti, Manraj Virk, Yakdehikandage S Costa, Sarah Berger, Ortenc Hoxha, Trevor Jairam, Phavalan Rajendram, Brian J Murray, Mark I Boulos

Sleep Medicine · 2026-12 · 148 · 109232

DOI: 10.1016/j.sleep.2026.109232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sleep Medicine, 2026-12. Verfasst von Mariam Belghiti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Undergraduate MD…. Hauptthemen laut MEDLINE: Hypolipidemic Agents, Sleep, Sleep Quality. Die Arbeit nennt 47 Literaturangaben. Gefördert von: University of Toronto Temerty Faculty of Medicine, Branch Out Neurological Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: There is mixed evidence as to whether lipid-lowering agents impact sleep, with some patients reporting significant sleep disruption after starting these medications. Our objective was to determine the relationship between use of lipid-lowering agents and objective measures of sleep quality recorded via in-laboratory polysomnography. METHODS: In this cross-sectional retrospective study, we examined data from patients who underwent diagnostic in-laboratory polysomnography at Sunnybrook Sleep Laboratory, an academic tertiary care sleep center. Self-reported questionnaires were used to ascertain use of any lipid-lowering agent and medical comorbidities. Multivariable linear regression models were utilized to analyze the association between use of lipid-lowering agents, including specific classes, with objective polysomnography-derived measures of sleep (i.e. sleep efficiency, total sleep time, REM latency, sleep onset latency, and wake time after sleep onset). RESULTS: We included 3754 patients (mean age±SD = 54.7 ± 16.4 years; 47.5% male; mean BMI±SD = 29.0 ± 6.64 kg/m2). Overall, 1055 patients were found to be using lipid-lowering agents with atorvastatin being the most common, followed by rosuvastatin, cholesterol absorption inhibitors, simvastatin, pravastatin, fibrates, and bile acid sequestrants. After adjusting for age, sex, body mass index, relevant comorbidities, obstructive sleep apnea and its severity, habits that worsen sleep, and other medication classes that impact sleep, the use of atorvastatin was found to significantly decrease sleep efficiency (β = -1.95; 95% CI = -3.71 to -0.19; p = 0.030). The use of other lipid-lowering agents, regardless of medication class, did not significantly impact sleep. CONCLUSION AND RELEVANCE: The use of atorvastatin may be associated with negative impacts to patients' sleep, though the magnitude of change is small. Clinicians should be aware of these effects and counsel patients accordingly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypolipidemic AgentsSleepSleep QualityHumansFemaleMalePolysomnographyCross-Sectional StudiesRetrospective StudiesMiddle AgedSleep DurationAdultAtorvastatinAgedSurveys and Questionnaires

Stichwörter der Autor:innen

(1-7): lipid-lowering agentsPolysomnographySleep qualitySleep quantityStatins

Substanzen

Hypolipidemic AgentsAtorvastatin

Autor:innen und Institutionen

  • Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Undergraduate MD Program, Temerty Faculty of Medicine, University of Toronto, Toronto,…
  • Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
  • Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Undergraduate MD Program, Memorial University, St. John's, Newfoundland and Labrador,…
  • Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada.
  • Department of Clinical Neurological Sciences, London Health Sciences Centre, Schulich School of Medicine, Western University, London, Ontario, Canada.

Förderung

  • University of Toronto Temerty Faculty of Medicine
  • Branch Out Neurological Foundation

Zitieren

APA

Belghiti, M., Virk, M., Costa, Y. S., Berger, S., Hoxha, O., Jairam, T., Rajendram, P., Murray, B. J., & Boulos, M. I. (2026). Lipid-lowering agent use and changes to sleep. Sleep Medicine, 148, 109232. https://doi.org/10.1016/j.sleep.2026.109232

Vancouver

Belghiti M, Virk M, Costa YS, Berger S, Hoxha O, Jairam T, et al. Lipid-lowering agent use and changes to sleep. Sleep Medicine. 2026;148:109232. doi:10.1016/j.sleep.2026.109232

BibTeX
@article{Belghiti2026,
  author = {Belghiti, Mariam and Virk, Manraj and Costa, Yakdehikandage S and Berger, Sarah and Hoxha, Ortenc and Jairam, Trevor and Rajendram, Phavalan and Murray, Brian J and Boulos, Mark I},
  title = {Lipid-lowering agent use and changes to sleep},
  journal = {Sleep Medicine},
  year = {2026},
  volume = {148},
  pages = {109232},
  doi = {10.1016/j.sleep.2026.109232}
}
Kostenlos starten →